Jiang Ni, Guo Qiang, Luo Qing
Cancer Laboratory, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Department of Pathology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
J Gastrointest Oncol. 2022 Apr;13(2):615-629. doi: 10.21037/jgo-22-233.
The long non-coding RNA, integrin subunit beta 1 (ITGB1) divergent transcript (ITGB1-DT), is known to be involved in cancer progression and associated with the poor prognosis of cancer patients. At present, the role of ITGB1-DT in stomach adenocarcinoma (STAD) has not been reported.
The expression level of ITGB1-DT was detected in normal gastric and STAD tissues from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases. A receiver operating characteristic (ROC) analysis was used to evaluate the role of ITGB1-DT in diagnosing STAD. The relationship between ITGB1-DT overexpression and clinicopathological features, prognosis, and immune-infiltrated cells in STAD were explored using correlation, survival, and Cox regression analyses. A cell model of ITGB1-DT interference was constructed to explore the roles of ITGB1-DT on STAD cell proliferation and migration, and the signaling mechanism was investigated using Gene Set Enrichment Analysis (GSEA).
ITGB1-DT was expressed up-regulated in STAD tissues. ITGB1-DT overexpression was associated with the T stage, therapeutic effect, overall survival, progression-free interval status, and poor prognosis in STAD patients. ITGB1-DT overexpression was valuable in diagnosing STAD and a negative factor affecting the prognosis of STAD patients. Interference with ITGB1-DT expression inhibited STAD cell proliferation, invasion, and migration. GSEA results showed that ITGB1-DT may be involved in STAD progression through the insulin, p53, mechanistic target of rapamycin kinase (MTOR), and other signaling pathways. Overexpression of ITGB1-DT was significantly correlated with the levels of STAD B cells, T cells, T helper cells, CD8 T cells, cytotoxic cells, and other immune cells.
ITGB1-DT was overexpressed and associated with poor prognosis in STAD. Interference with ITGB1-DT expression may delay the progression of STAD to improve the prognosis of STAD patients.
长链非编码RNA，整合素亚基β1（ITGB1）差异转录本（ITGB1-DT），已知参与癌症进展并与癌症患者的不良预后相关。目前，ITGB1-DT在胃腺癌（STAD）中的作用尚未见报道。
从癌症基因组图谱（TCGA）和基因型-组织表达（GTEx）数据库中检测正常胃组织和STAD组织中ITGB1-DT的表达水平。采用受试者工作特征（ROC）分析评估ITGB1-DT在诊断STAD中的作用。利用相关性分析、生存分析和Cox回归分析探讨ITGB1-DT过表达与STAD临床病理特征、预后及免疫浸润细胞之间的关系。构建ITGB1-DT干扰细胞模型，探讨ITGB1-DT对STAD细胞增殖和迁移的作用，并通过基因集富集分析（GSEA）研究其信号传导机制。
ITGB1-DT在STAD组织中表达上调。ITGB1-DT过表达与STAD患者的T分期、治疗效果、总生存期、无进展生存期状态及不良预后相关。ITGB1-DT过表达对STAD诊断有价值，且是影响STAD患者预后的负性因素。干扰ITGB1-DT表达可抑制STAD细胞增殖、侵袭和迁移。GSEA结果显示，ITGB1-DT可能通过胰岛素、p53、雷帕霉素激酶机制性靶点（MTOR）等信号通路参与STAD进展。ITGB1-DT过表达与STAD B细胞、T细胞、辅助性T细胞、CD8 T细胞、细胞毒性细胞等免疫细胞水平显著相关。
ITGB1-DT在STAD中过表达且与不良预后相关。干扰ITGB1-DT表达可能延缓STAD进展，改善STAD患者预后。
